Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

2019-06-01
Price :
Published : Jun-2019
No. of Pages : 140

Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for 2018 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2018. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the five years.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical
Publisher : GlobalData
More Reports
Title Price Buy Now

Ambulatory Surgical Centers Market by Product (EHR, Practice Management, Telehealth, Healthcare Analytics, PHM, Supply Chain Management, RCM, Surgical planning, Quality Management), Specialty Type (Single, Multi-specialty) – Global Forecast to 2025

The Ambulatory Surgical Centers market is projected to reach USD 7.2 billion by 2025 from 2.1 billion in 2020 at a CAGR of 27.6% during the forecast period.There is a growing inclination across the globe towards the adoption of healthcare IT technologies due to the increasing need to deliver quality care to patients while curtailing escalating healthcare costs. These robust IT solutions are designed to streamline workflow in healthcare systems, reduce expenses, and facilitate compliance with stringent regulatory guidelines. By-products and services, the healthcare providers segment accounted for the largest share of the Ambulatory Surgical Centers market in 2018 Based on products and services, the Ambulatory Surgical Centers market is segmented into healthcare provider solutions, h......
$5650

Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) – Global Forecast to 2025

“Risk-based monitoring (RBM) software market is projected to grow at a CAGR of 13.3%.” The RBM software market is expected to reach USD 511 million by 2025 from USD 273 million in 2020, at a CAGR of 13.3% during the forecast period. The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide. Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials “The Enterprise RBM Software segment to hold the largest market share in 2020.” Based on type, the RBM software market is segmented into Enterprise RB......
$5650

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

“The veterinary vaccines market is projected to grow at a CAGR of 7.2% during the forecast period (2020–2025).” The global veterinary vaccines market size is projected to reach USD 11.3 billion by 2025 from USD 8.0 billion in 2020, at a CAGR of 7.2%. The growth of this market is driven majorly by factors such as the initiatives by various government agencies and animal associations to maintain animal health, rising incidence of zoonotic diseases, growth in the companion animal population, and the rising demand for animal-derived food products are driving the growth of this market. On the other hand, the high storage cost of vaccines is restraining market growth. “By technology, the recombinant vaccines segment is expected to grow at the highest CAGR during the forecast period......
$4950

COVID-19 Impact on Vaccines & Drugs Market – Global Forecast to 2025

"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period." The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development. "The global COVID 19 drugs market is projected to grow at a CAGR of -57.8% during the forecast period." The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs......
$5650

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides ......
$1000

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028

Colorectal Cancer: Global Drug Forecast and Market Analysis to 2028 Summary Colorectal cancer (CRC) occurs in the large intestine or large bowel. It is the third most common cancer globally and is one of the most common causes of cancer deaths in the world. Early stage CRC is commonly treated with surgery, while metastatic colorectal cancer (mCRC) treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors, primarily Roche's Avastin, and epidermal growth factor receptor (EGFR) inhibitors. GlobalData valued the CRC market at $6.4B in 2018. This market is defined as sales of generic chemotherapy and major branded drugs commonly prescribed for CRC patients across the 8MM. GlobalData expects the market to increase to $8.1B in 2028 at a Compound A......
$10995

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast

Coronavirus Disease 2019 (COVID-19) Sector Forecast: Analyst Consensus Sales Forecast Summary This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Despite the rapid development of COVID-19 therapies being developed the majority of the COVID-19 pipeline is in early stage development so there are few forecasts available. Currently there are three drugs indicated for COVID-19 which have analyst consensus forecasts available. Scope This 27-page report gives important, expert insight you won't find in any other source. 7 figures throughout the report illustrate major points and trends in COVID sales forecasts and company pipelines. This report is require......
$495

Medical Marijuana: Consumers’ Perspectives in the US and UK

Medical Marijuana: Consumers' Perspectives in the US and UK Summary GlobalData's Medical Marijuana, Consumers' Perspectives report combines an extensive survey and analysis of patients' perspectives in the US and UK to provide an in-depth consumer-centered review of the medical marijuana market. Components of the report include an in-depth breakdown of the survey and its respondents, detailed analysis of consumers' concerns and opinions of medical and recreational marijuana, information from interviews with patients receiving treatment with medical marijuana in the US and UK, and an assessment of the impact of the COVID-19 pandemic on the medical marijuana space. The report evaluates trends across different age groups, health statuses, and other parameters to inform insightful compariso......
$7995

Pharmaceutical Trade and Supply Chain Survey – Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact

Pharmaceutical Trade and Supply Chain Survey - Q1 2020: Coronavirus Disease 2019 (COVID-19) Sector Impact Summary GlobalData's Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey - Q1 2020 provides in-house analyst expertise on the results of a 5 minute survey of 136 GlobalData Pharma clients and prospects, which was fielded from March 13, 2020 to March 24, 2020. Scope - This report provides an assessment of how the pharmaceutical industry perceives the supply chain disruption caused by the COVID-19 pandemic, including the challenges associated with clinical trials, logistics, API and finished dose manufacturing. - Since the first case was diagnosed in Wuhan, China, in December 2019, COVID-19 cases have continued to rise rapidly across the gl......
$1495

Social Media: Coronavirus Disease (COVID-19) Sector Impact

Social Media: Coronavirus Disease (COVID-19) Sector Impact Summary The highly contagious coronavirus (SARS-CoV-2), dubbed COVID-19 (formerly 2019-nCoV), which emerged at the close of 2019, has led to a medical emergency across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. This report analyzes GlobalData's social media Influencer dashboards to understand Influencer trends since the pandemic began and what key Influencers are discussing online about COVID-19. across the world, with the World Health Organization (WHO) officially declaring the novel coronavirus a pandemic on March 11, 2020. Scope - This report analyzes Influencer trends since the pandemic began and what assesses what key Influencers are discussi......
$995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy